

THE COUNCIL FOR TOBACCO RESEARCH-U.S.A., INC.

SUPPORTING BIOMEDICAL INVESTIGATION

900 THIRD AVENUE
NEW YORK, NY 10022
(212) 421-8885

JAMES F. GLENN, M.D.
CHAIRMAN AND PRESIDENT
CHIEF EXECUTIVE OFFICER

April 27, 1994

Aharon Razin, Ph.D.
Department of Cellular Biochemistry
Hebrew University of Jerusalem Medical School
P.O.B. 12272
Jerusalem 91120, ISRAEL

Re: Grant No. 3022A

Dear Dr. Razin:


The Council for Tobacco Research, USA, Inc. (CTR), is pleased to award you a continuation grant in the amount of \$58,360 (including indirect costs) for the period from July 1, 1994 through June 30, 1995 for the study proposed in your application "DNA Modification in Parental Imprinting." It is understood that this grant is made subject to acceptance by institutional authorities. Also, many applications to CTR indicate partial or complete overlap with applications to other agencies. If the latter result in awards, we should be notified promptly so that we can negotiate an appropriate adjustment of our award.

The award is made without guarantee of support beyond June 30, 1995, even though we recognize that your original application proposed a study extending two years beyond that date. Therefore, if by November 30, 1994 you submit to us a formal renewal application, including a report of your progress, your request will receive consideration.

Your attention is called to the enclosed "Important Procedural Information for Grantees". Please fill in the attached "Notice of Research Project" and return it to me. Please contact Dr. Harmon McAllister of our scientific staff on matters concerning your grant and keep us informed about the progress of your study.

As Principal Investigator, you should know that **CTR recovers unexpended balances over \$1,000 at the end of each grant year (see attached "Financial Requirements" for specific details)**. We suggest that you personally keep an accurate record of expenditures and commitments. Please note that **year-end deficits cannot be recovered from CTR**, even from funds awarded in a subsequent year. Moreover, our failure to receive timely annual financial statements from your grants office will stop further grant payments. Appropriate forms will be sent to your financial officer at the end of the grant year. Administrative problems are relatively rare and we hope that this statement of our fiscal procedures will obviate any possible misunderstandings.

Sincerely,



James F. Glenn, M.D.

Encl.
cc: Prof. Ilan Chet
JFG:mm

bcc: Auditors, ROK, LP, File
M/M, Monitors

Plmt Razin
Dr (Israel)
copy of Prog Report
7/6/94